Alterations in the chemical modifications that control gene expression, known as epigenetics, have proven to be one of the most characteristic properties of all human tumors. This realization has generated the development of intense pharmacological research to find drugs that act at this level against cancer. Today there are nine epigenetic drugs approved for use in oncology, especially in leukemias, lymphomas and soft tissue tumors. However, a mystery remains: Why do some patients respond clinically to these compounds others show resistance to their action?
Leave A Comment